Topics

Glioblastoma | Treatment | Chemotherapy | Temozolomide | Administration

Home > Publications > Topics > Glioblastoma > Treatment > Chemotherapy > Temozolomide > Administration

Geurts M, Berchtold L, Koenig F, Nabors B, Reardon DA, Tonn JC, Stupp R, Gorlia T, Weller M, Preusser M; EORTC Brain Tumor Group.
Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?
Neurooncol Pract. 2025 Jan 17;12(2):291-300. doi: 10.1093/nop/npaf006. PMID: 40110070. Observational study. ˍ